Register
Healthed-White-on-Blue
  • Clinical Takeaway

Prostate cancer screening – Your questions answered

Expert/s: A/Prof Jeremy Grummet
   Rated 5 / 5 stars

Save

CPD for this activity

Educational Activities (EA)

0.5 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0.5 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

0 hours

These are activities that use your work data to ensure quality results.

EA
0.5 mins

Educational Activities (EA)
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0.5 mins

Reviewing Performance (RP)
These are activities that require reflection on feedback about your work.

MO
0 mins

Measuring Outcomes (MO)
These are activities that use your work data to ensure quality results.

Listen to the episode

Description

The questions answered in this podcast are listed below.
They were compiled by GPs and health professionals around Australia.

1. My patient was told by a doctor that duodart may cause cancer – thoughts?
2. What’s the utility of PSA in the monitoring for relapse of metastatic prostate cancer where treatment had been deemed successful at suppressing growth, but prostatectomy had not been performed? I know this is not a screening question as such, but it sounds like to me the oncology team is using PSA as a “screening” test for relapse in this patient in this context since he is not on active treatment?
3. How important is “above the mean” but < 3 PSA level mean?
4. What about rate of rise of PSA? Link with prostate cancer?
5. Are we routinely check PSA for men >50 year old every 2 years in general practice?
6. Will you do random sampling via transperineal biopsy for patients who are MRI contraindicated? Or is there another imaging modality e.g. PET scan
7. Healthy man of 70 year old, should or should not he have PSA testing?
8. Is a PSA level of 3 used as cut off across age groups?
9. People with family history – How do you screen? I learnt a few years ago  0.35 rise per year is acceptable more than that need to be investigated. What are the guidelines with or without family history to screen for prostate cancer?
10. Is the upper age limit for PSA likely to change given that men are living longer?
11. How many patients on active surveillance actually develop metastatic prostate cancer and missed the chance of curative treatment?
12. If PSA is >6, will the patient get Medicare rebate for repeating the PSA 1-3 months later? I was under impression PSA Medicare rebate is only available once every 12 months
13. What management or follow up is recommended for men with PSA within the normal range but above the median for their age group?
14. Why was the transrectal biopsy ever done instead of trans perineal from the get-go? Is it technically easier?
15. What MRI is recommended for detecting prostate cancer?
16. How far are we to use AI for reporting MRI prostate?
17. Why we don’t do MRI screening rather PSA
18. For patient with PSA > 3.0, if repeat test after 1-3 months showed PSA < 3.0, do we repeat screening again in 2 years, or earlier?
19. What are some comments you might have about risk mitigation in the diagnosis of prostate cancer?

 

Guest: A/Prof Jeremy Grummet, Urologist

Host: Dr David Lim, GP and Medical Educator

Total time: 43 minutes

 

Last Updated: 27 Feb, 2024

Rate this podcast
Help your colleagues find podcasts they'll enjoy by rating this podcast out of five stars.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Daryl Cheng

A/Prof Daryl Cheng

RSV Prevention in Infants and Pregnant Women

Prof Jason Ong

Prof Jason Ong

STIs – Common and Tricky Cases

Dr Terri Foran

Dr Terri Foran

Role of Testosterone During Menopause - Evidence vs Hype

Dr Fiona Chan

Dr Fiona Chan

Vision and Driving Fitness: Key Insights for Health Practitioners

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

15 April 2025
Register Now
A/Prof Jeremy Grummet

expert

A/Prof Jeremy Grummet

Urological Surgeon; Director of Urology, Alfred Health, Melbourne

Recent articles

  • Neurology

Alzheimer’s blood test coming soon to Australia 

  • Women's health

Preconception metabolic health – the consult with lifetime benefits

Find your area of interest

Share this

Next up

Browse the latest podcasts from Healthed.

View more
Women's health

It's so hot right now and healthcare professionals are all feeling the heat around menopause management

In today's podcast, Dr Rebecca South discusses key messages from two valuable menopause meetings, which address controversies surrounding higher dose oestrogen, potential testosterone overuse, and implications for menopause management in general practice.
Dermatology

Nail infections

In today’s podcast, Dr Philip Tong explores the causes of nail infections, their link to paronychia and nail deformities, and effective treatment options, including topical and systemic therapies.

Education by clinicians, for clinicians

Get the app

Site

Company

Connect

Legal

Discover

Healthed

CPD platform

You have completed the Educational Activities (EA) component of this activity.

Select ‘Confirm & claim CPD‘ to confirm you have engaged with this activity in its entirety and claim your CPD.

You will be taken to explore further CPD learning available to you.

Cancel
Confirm & claim CPD

Join the upcoming Healthed webcast on Tuesday 1st April

Menopause and MHT

Multiple sclerosis vs antibody disease

Using SGLT2 to reduce cardiovascular death in T2D

Peripheral arterial disease

Registration essential